What hepatologists need to know about COVID-19?

OpenAlex İngilizce

associated with severe cases. A retrospective analysis of patients from Wuhan examining the clinical course and risk factors for mortality reported higher mortality in patients with alanine aminotransferase (ALT) elevation, reduced platelets and reduced albumin levels at the time of admission. This is more likely to be a result of reactive immune response characterized by a cytokine storm with multi-organ failure, rather than liver injury. If the pattern of hepatocellular injury is aspartate aminotransferase predominant, this may suggest myositis, cytokine release syndrome, ischemia/hypotension, or a drug-induced liver injury. Hypoalbuminemia observed in COVID-19 cases is generally related to the severe inflammatory response. ACE2 receptors are also expressed in the cholangiocytes, and elevation of gamma-glutamyl transferase-a biomarker for cholangiocyte injury -was reported in 54% of hospitalized patients with COVID-19. It is unclear whether a direct virus-induced cytopathic effect and/or immune damage are responsible for the liver function test abnormalities. Interestingly, postmortem examination of a patient with acute respiratory distress syndrome did not show viral inclusions in the liver and the histology showed moderate microvesicular steatosis and mild lobular and portal activity, indicating an injury caused by either SARS-CoV-2 infection or drug-induced liver injury. patotoxicity of medications is a key consideration within the differential diagnosis of liver function test abnormalities. There are currently no approved drugs for SARS-CoV-2, and clinical trials are ongoing. Using the experience of China and Europe, each country implemented different treatment protocols. Hydroxychloroquine and azithromycin have not been associated with ALT abnormalities and an extremely rare cause of acute liver injury. Lopinavir/ ritonavir are approved protease inhibitors (PIs) for human immunodeficiency virus, which promised some hope by showing in vitro antiviral effect on SARS-CoV-2. However, after the results of a clinical trial of patients with severe COVID-19 that showed no proven efficacy of lopinavir/ritonavir compared to no treatment, The risk of lopinavir/ritonavir-associated hepatotoxicity is low. Favipiravir is an RNA polymerase inhibitor, approved for influenza in Japan and Turkey also got the supply of favipiravir from China. Favipiravir is metabolized by aldehyde oxidase and xanthine oxidase. CYP450 iso-enzymes are not involved in metabolism. Transaminases may increase during favipiravir treatment. Remdesivir is a nucleoside analogue/viral RNA polymerase inhibitor that inhibits SARS-CoV-2 in vitro, The clinical trials for the efficacy and safety of remdesivir are ongoing. Tocilizumab -humanised monoclonal antibody, which targets interleukin-6 receptor -is recommended for the treatment of cytokine release syndrome